Feature | March 19, 2013

Survival of Sapien High-Risk Patients Equivalent to Surgery at Three Years

Late-breaking data at ACC 2013 further support Sapien as alternative to surgery

Edwards Sapien, PARTNER, 3 year followup

March 19, 2013 — The three-year results of a pivotal clinical study comparing the Edwards Sapien transcatheter heart valve and open-heart surgery demonstrated comparable outcomes. These new data from The PARTNER Trial were presented today as a late-breaking clinical trial at the American College of Cardiology's (ACC) 62nd Annual Scientific Session in San Francisco.

"These three-year data from The PARTNER Trial strengthen the evidence that the Sapien valve is a safe and less-invasive alternative for those patients who need valve replacement, but are at high surgical risk," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves. "The availability of the Sapien valve encourages the many untreated patients to work with a Heart Team to determine whether transcatheter valve replacement or surgery is the right option for them."

At three years, all-cause mortality for patients treated with the Edwards Sapien transcatheter aortic valve replacement (TAVR) delivered via the femoral artery or a small incision between the ribs was statistically equivalent to that of patients who had received open-heart surgical aortic valve replacement (AVR). Symptom improvement and valve performance was similar in both groups and was maintained through the three years of patient follow-up. The incidence of stroke between TAVR and surgery patients was also comparable. (See table below for specific data points.)

The PARTNER Trial is the first randomized, controlled trial of a transcatheter aortic valve in the United States. The high-risk surgery cohort (Cohort A) of the trial enrolled between May 2007 and Sept. 2009 and studied 699 patients with severe, symptomatic aortic stenosis deemed at high risk for traditional open-heart surgery. Patients were evaluated by a multi-disciplinary Heart Team and randomized to receive either traditional open-heart surgery or the Sapien valve with transfemoral or transapical delivery.

The Food and Drug Administration (FDA) approved the Sapien valve in November 2011 for the treatment of inoperable patients, and expanded the indication to high-risk surgical patients in October 2012.

The PARTNER Trial, High-Risk Surgical Cohort (Cohort A)(i)

               1-year                 2-year                 3-year        
          Sapien/Surgery value    Sapien/Surgery value    Sapient/Surgery value 
mortality     24.3 / 26.8  0.45               33.9 / 35.0  0.78                    44.2 / 44.8 0.483 
Stroke:        6 / 3.2  0.08                      7.7 / 4.9  0.17                        8.2 / 9.3 0.763

Note: These data refer to the intention-to-treat (ITT) population.

For more information: edwards.com

Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies
News | Stem Cell Therapies| November 13, 2015
A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method...
angina, abnormal heart blood flow, female-pattern heart disease, Cedars-Sinai Heart Institute study, AHA Scientific Sessions
News | Cardiac Diagnostics| November 13, 2015
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, a new Cedars-Sinai Heart Institute...
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
pharmacist-physician collaboration, high blood pressure control, minority and low-income populations
News | Hypertension| November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of pa
Neovasc, Tiara, transcatheter mitral valve, TMVR

The Neovasc Tiara transcatheter mitral valve is currently being tested in U.S. and international clinical trials. 

Feature | Heart Valve Repair| November 12, 2015 | Dave Fornell
The advent of transcatheter valve repair and replacement technologies is one of those rare instances where there is a
obese kids, eight years old, heart disease, MRI, Linyuan Jing
News | Cardiac Diagnostics| November 11, 2015
Imaging tests of obese children — some as young as 8 years old — showed signs of significant heart disease and heart...
Pradaxa, warfarin, safety and effectiveness, NVAF, non-valvular atrial fibrillation, clinical trial, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies| November 11, 2015
Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new interim analysis from a...
Overlay Init